Monitoring Protocols for Peptide Use

Pre-Cycle Baseline Testing

This overview draws on what labels and trials of related approved drugs measured, plus what users report; no trial has tested a schedule for research-use peptides. The blood work schedule guide covers each phase in depth.

Essential Baseline Panel

The Egrifta WR (tesamorelin) label asks for a glucose check before starting. Users commonly describe a panel 2-4 weeks ahead, usually including:

Test Category	Specific Markers
Complete Blood Count	RBC, WBC, hemoglobin, hematocrit, platelets
Comprehensive Metabolic	Glucose, electrolytes, BUN, creatinine, liver enzymes
Lipid Panel	Total cholesterol, LDL, HDL, triglycerides
Hormonal	Total/free testosterone, estradiol, LH, FSH (plus progesterone for women)
Thyroid	TSH, free T3, free T4
GH axis	IGF-1 (steadier than a single GH reading)
Inflammation	CRP-hs, ESR (optional)
Glucose control	Fasting insulin, HbA1c

Optional Baseline Tests

Some panels add vitamin D (25-OH), B12 and folate, an iron panel (ferritin, TIBC), prolactin or DHEA-S.

On-Cycle Monitoring Schedule

Growth Hormone Peptides (GHRPs, GHRHs)

In the 2-year MK-677 trial in 65 adults aged 60-81, IGF-1 rose into the young-adult range while fasting glucose rose about 5 mg/dL. The Egrifta WR label calls for IGF-1 monitoring and periodic glucose checks; by week 26, 5% of tesamorelin patients had an HbA1c of 6.5% or higher (1% on placebo). Users commonly report this pattern, a convention rather than a tested protocol:

Commonly Reported Timepoint	Tests
Week 4	IGF-1, fasting glucose, insulin
Week 8	Hormonal panel, metabolic panel
Week 12	IGF-1, HbA1c, lipids

Recovery Peptides (BPC-157, TB-500)

A 2025 IV pilot of BPC-157 found no changes in organ or glucose markers, but it had only 2 participants. Users who test commonly report a CBC and liver enzymes around week 4, then a basic metabolic panel at week 8 if they continue.

Metabolic Peptides (MOTS-c, etc.)

MOTS-c has no label-based schedule; users who test commonly report glucose, insulin and lipid checks. By contrast, the Wegovy (semaglutide) and Zepbound (tirzepatide) labels call for glucose checks in people with diabetes and kidney checks after vomiting or diarrhea.

Post-Cycle Testing

Timing

In a 2006 CJC-1295 trial, IGF-1 stayed above baseline for up to 28 days after multiple doses. Users commonly report retesting 2-4 weeks after the last dose of a short-acting peptide, or 4-6 weeks after a longer-acting one. IGF-1 and fasting glucose are the usual repeats; the post-cycle assessment guide covers how long markers take to settle.

Interpreting Results

Reference ranges differ between labs, so results are read against the range on the report.

IGF-1 Levels

IGF-1 falls with age, so labs use age-specific ranges. Forum posts often treat roughly 250-350 ng/mL as a goal, but that isn't a clinical target. The Egrifta WR label uses standard deviation scores (SDS): 47% of patients exceeded 2 SDS at 26 weeks, and persistent values above 3 SDS are its example of when to consider stopping.

Glucose/Insulin Markers

American Diabetes Association cutoffs:

Marker	Normal	Prediabetes	Diabetes
Fasting glucose	Under 100 mg/dL	100-125 mg/dL	126 mg/dL or higher
HbA1c	Under 5.7%	5.7-6.4%	6.5% or higher

Fasting insulin and HOMA-IR have no agreed cutoff, so the trend against a person's own baseline says more than one value.

Thyroid Markers

Thyroid ranges vary by lab, and peptide-guide "optimal" ranges aren't a clinical standard. Tesamorelin didn't meaningfully change TSH in trials. The Wegovy label calls routine calcitonin tests or thyroid ultrasound "of uncertain value," despite its boxed warning about thyroid tumors in rodents.

Red Flags Requiring Immediate Action

Stop Peptide Use and Consult Physician

Commonly listed reasons to stop and see a clinician promptly:

Fasting glucose of 126 mg/dL or higher on repeat testing
Frequent urination or constant thirst
A marked rise in liver enzymes
New joint pain or hand swelling (possible GH excess)
Visual disturbances
Severe headaches
Unexplained edema
Chest pain, or hives and trouble breathing

Signs Often Linked to High GH or IGF-1

The Egrifta WR label describes fluid retention, with symptoms such as carpal tunnel syndrome that resolved after stopping. Users also mention:

IGF-1 well above the lab's range
Water retention that doesn't settle
Sleep disturbances or irritability

Many report lowering or pausing a dose in response, which no study has tested. More in warning signs by peptide class.

Specialized Testing Considerations

For Long-Term Users (>1 year)

No trial has followed users past a year. Some clinics describe an annual review:

Echocardiogram
Colonoscopy (per age guidelines)
Skin check
DEXA scan
Sleep study (if symptoms)

For Diabetics or Pre-Diabetics

The Egrifta WR label calls for retinopathy checks in patients with diabetes. The GLP-1 labels warn of low blood sugar when combined with insulin or a sulfonylurea. HbA1c every 3 months and continuous glucose monitoring are commonly described.

Working with Healthcare Providers

Finding the Right Provider

People who want lab monitoring report using:

Anti-aging or sports medicine specialists
Endocrinologists familiar with performance contexts
Telemedicine options for monitoring

What to Communicate

Results are easier to interpret when the clinician has the complete peptide and supplement list, all symptoms and previous lab results.

What We Still Don't Know

The GH-axis data come from older adults (MK-677) and people with HIV-associated abdominal fat (tesamorelin), not younger lifters using gray-market vials of uncertain content. As of October 2026, no research-use peptide has a trial-tested monitoring schedule.